FrancophonIA/ELRC3.0 huggingface dataset:
English: Do not take Eliquis if: - you are allergic to apixaban or any of the other ingredients of this medicine (listed in section 6) - you are bleeding excessively - you have a disease in an organ of the body that increases the risk of serious bleeding (such as an active or a recent ulcer of your stomach or bowel, recent bleeding in your brain) - you have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy) - you are taking medicines to prevent blood clotting (e.g., warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open, or if a tube is inserted into your blood vessel (catheter ablation) to treat an irregular heartbeat (arrhythmia).
Croatian: Nemojte uzimati Eliquis - ako ste alergični na apiksaban ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) - ako obilno krvarite - ako imate bolest nekog tjelesnog organa koja povećava rizik od značajnog krvarenja (poput aktivnog ili nedavnog vrijeda na želucu ili crijevima, nedavnog krvarenja u mozgu) - ako imate bolest jetre koja povećava rizik od krvarenja (jetrena koagulopatija) - ako uzimate lijekove koji sprječavaju zgrušavanje krvi (npr. varfarin, rivaroksaban, dabigatran ili heparin), osim kod promjene liječenja antikoagulansima, za održavanje prohodnosti venskog ili arterijskog puta heparinom (koji dobivate tim putem) ili ako je cjevčica umetnuta u Vašu krvnu žilu (kateterska ablacija) radi liječenja nepravilnih otkucaja srca (aritmija).
English: The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or Cmax.
Croatian: Primjena apiksabana u dozi od 10 mg s famotidinom u dozi od 40 mg nije utjecala na AUC ni Cmax apiksabana.
English: In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment.
Croatian: U ispitivanju AMPLIFY-EXT randomizirano je ukupno 2482 bolesnika u skupine koje su liječene apiksabanom u dozi od 2,5 mg dvaput na dan peroralno, apiksabanom 5 mg dvaput na dan, ili placebom tijekom 12 mjeseci nakon dovršetka 6-mjesečnog do 12-mjesečnog početnog liječenja antikoagulansom.
English: Medicinal products associated with serious bleeding are not recommended concomitantly with Eliquis, such as: thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran and sulfinpyrazone.
Croatian: Ne preporučuje se istodobna primjena lijeka Eliquis s lijekovima koje se povezuje sa značajnim krvarenjem, poput trombolitika, antagonista GPIIb/IIIa receptora, tienopiridina (npr. klopidogrela), dipiridamola, dekstrana i sulfinpirazona.
English: Apixaban showed a reduction in recurrent symptomatic VTE or VTE- related death across the different levels of center TTR; within the highest quartile of TTR according to center, the relative risk for apixaban vs enoxaparin/warfarin was 0.79 (95% CI, 0.39, 1.61).
Croatian: Apiksaban je smanjio broj slučajeva ponavljajućeg simptomatskog VTE ili smrtnog ishoda povezanog s VTE pri različitim razinama centralnog TTR-a; u najvišem kvartilu TTR-a u odnosu na centar, relativni rizik za apiksaban u odnosu na enoksaparin/varfarin iznosio je 0,79 (95% CI, 0,39; 1,61).
English: Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events.
Croatian: Bolesnici su bili randomizirani 1:1 u skupinu liječenu apiksabanom ili u skupinu liječenu heparinom i/ili antagonistom vitamina
English: No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).
Croatian: Nije potrebno prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije (vidjeti dijelove 4.4 i 5.2).
English: Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively.
Croatian: U kliničkim je ispitivanjima primijećeno dodatno izlučivanje putem žuči, a u nekliničkim studijama izravno putem crijeva.
English: Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., diltiazem, naproxen, clarithromycin, amiodarone, verapamil, quinidine) are expected to increase apixaban plasma concentration to a lesser extent.
Croatian: Očekuje se da će djelatne tvari koje se ne smatraju snažnim inhibitorima CYP3A4 i P-gp-a (npr. diltiazem, naproksen, klaritromicin, amiodaron, verapamil, kinidin) u manjoj mjeri povećati koncentraciju apiksabana u plazmi.
English: Enoxaparin/ Warfarin N=2,689 n (%)
Croatian: Enoksaparin/ varfarin N=2689 n (%)
English: Therefore, it is not recommended in these patients.
Croatian: Stoga se primjena apiksabana u takvih bolesnika ne preporučuje.
English: Crushed Eliquis tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours.
Croatian: Zdrobljene tablete Eliquis stabilne su u vodi, 5%-tnoj otopini glukoze u vodi, soku od jabuke i pireu od jabuke do 4 sata.
English: - Skin rash - Itching - Hair loss - Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing.
Croatian: - Kožni osip - Svrbež - Gubitak kose - Alergijske reakcije (preosjetljivost) koje mogu izazvati: oticanje lica, usana, usta, jezika i/ili grla i otežano disanje.
English: In patients taking apixaban for the prevention of VTE following hip or knee replacement surgery, the results demonstrate a less than 1.6-fold fluctuation in peak-to-trough levels.
Croatian: U bolesnika koji uzimaju apiksaban za prevenciju VTE nakon kirurškog zahvata ugradnje endoproteze kuka ili koljena, rezultati pokazuju da je fluktuacija između najviše i najniže razine manja od 1,6 puta.
English: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Croatian: Prevencija venskih tromboembolijskih događaja (VTE) u odraslih bolesnika podvrgnutih elektivnom kirurškom zahvatu ugradnje endoproteze kuka ili koljena.
English: Intracranial, n Major + CRNM† All
Croatian: Intrakranijalno, n Veliko + klinički značajno ali koje nije veliko
English: The recommended dose is one tablet of Eliquis 2.5 mg twice a day if:
Croatian: Preporučena doza je jedna Eliquis 2,5 mg tableta dvaput na dan ako:
English: By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development.
Croatian: Inhibicijom aktivnosti faktora Xa apiksaban sprječava stvaranje trombina i nastanak tromba.
English: Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.
Croatian: Nakon primjene zdrobljene tablete apiksabana od 5 mg suspendirane u 60 ml 5%-tne otopine glukoze u vodi, te primijenjene putem nazogastrične sonde, izložnost je bila slična izloženosti uočenoj u drugim kliničkim ispitivanjima koja su uključivala zdrave ispitanike koji su primili jednu peroralnu dozu tablete apiksabana od 5 mg.
English: Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity.
Croatian: Tablica 3 u nastavku pokazuje predviđenu izloženost u stanju dinamičke ravnoteže i anti-faktor Xa aktivnost.
English: Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.
Croatian: Oba ispitivanja bila su randomizirana, dvostruko slijepa, multinacionalna, s paralelnim skupinama, u bolesnika sa simptomatskom proksimalnom dubokom venskom trombozom ili simptomatskom plućnom embolijom.
English: Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 µM.
Croatian: Pri koncentracijama do 20 µm apiksaban nije inducirao CYP1A2, CYP2B6, CYP3A4/5.
English: The most common general side effect of Eliquis is bleeding which may be potentially life threatening and require immediate medical attention.
Croatian: Za ta medicinska stanja, najčešća opća nuspojava lijeka Eliquis je krvarenje, koje može ugroziti život i iziskuje hitnu medicinsku pomoć.
English: In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value <0.0001] (see Table 11).
Croatian: U ispitivanju je apiksaban bio statistički uspješniji od enoksaparina/varfarina u primarnom sigurnosnom ishodu [Relativni rizik 0,31, 95% CI(0,17; 0,55), P-vrijednost <0,0001] (vidjeti Tablicu 11).
English: - for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).
Croatian: - u liječenju DVT, u liječenju PE i u prevenciji ponavljajućih DVT i PE (VTEt) nije potrebno prilagođavati dozu (vidjeti dio 5.2);
English: Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials.
Croatian: Bolesnici u kojih je povišena razina jetrenih enzima alanin aminotransferaze (ALT)/aspartat aminotransferaze (AST) > 2 x gornje granice normale (GGN) ili u kojih je ukupni bilirubin ≥ 1,5 x GGN nisu bili uključeni u klinička ispitivanja.
English: There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 9).
Croatian: Nije bilo statistički značajne razlike između apiksabana i ASK-a u incidenciji velikog krvarenja (vidjeti Tablicu 9).
English: When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant, as indicated in Table 1 below (see also section 5.1).
Croatian: Kada je indicirana prevencija ponavljajućih DVT i PE, s dozom od 2,5 mg dvaput dnevno treba započeti nakon dovršetka 6-mjesečnog liječenja apiksabanom u dozi 5 mg dvaput na dan ili s drugim antikoagulansom, kako je navedeno u Tablici 1 u nastavku (vidjeti također dio 5.1).
English: The following side effects are known if you take Eliquis to prevent blood clots from forming after hip or knee replacement operations.
Croatian: Sljedeće nuspojave mogu nastupiti ako Eliquis uzimate za sprječavanje nastanka krvnih ugrušaka nakon operacije ugradnje umjetnog zgloba kuka ili koljena.
English: Enoxaparin/Warfar in N=2,635 n (%)
Croatian: Enoksaparin/varfar in N=2635 n (%)
English: Fatal
Croatian: Smrtonosna
English: The following medicines may reduce the ability of Eliquis to help prevent blood clots from forming: - medicines to prevent epilepsy or seizures (e.g., phenytoin, etc.) - St John's Wort (a herbal supplement used for depression) - medicines to treat tuberculosis or other infections (e.g., rifampicin)
Croatian: Sljedeći lijekovi mogu umanjiti djelotvornost lijeka Eliquis u sprječavanju nastanka krvnih ugrušaka: - lijekovi koji sprječavaju epilepsiju ili epileptičke napadaje (npr. fenitoin itd.) - gospina trava (biljni nadomjestak koji se koristi kod depresije) - lijekovi za liječenje tuberkuloze ili drugih infekcija (npr. rifampicin)
English: The mean age was 69.9 years, the mean CHADS2 score was 2.0 and 13.6% of patients had prior stroke or TIA.
Croatian: Prosječna dob bila je 69,9 godinu, prosječan rezultat na ljestvici CHADS2 2,0, a 13,6% bolesnika prethodno je pretrpjelo moždani udar ili tranzitornu ishemijsku ataku (TIA).
English: Patients with elevated liver enzymes ALT/AST > 2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials.
Croatian: Bolesnici u kojih je povišena razina jetrenih enzima (ALT/AST > 2 x GGN) ili u kojih je ukupni bilirubin ≥ 1,5 x GGN nisu bili uključeni u klinička ispitivanja.
English: Relative Risk 95% CI
Croatian: 95% CI
English: The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section 4.4).
Croatian: Primjena lijeka Eliquis ne preporučuje se u bolesnika koji istodobno primaju sistemsku terapiju lijekovima koji su snažni inhibitori kako CYP3A4 tako i P-gp-a, poput azolnih antimikotika (npr. ketokonazol, itrakonazol, vorikonazol i posakonazol) i inhibitora HIV proteaze (kao na primjer ritonavir) (vidjeti dio 4.4).
English: There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 7).
Croatian: Nije bilo statistički značajne razlike između apiksabana i ASK-a u incidenciji velikog krvarenja (vidjeti Tablicu 7).
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER 2.5 mg (Symbol)
Croatian: BLISTER 2,5 mg (simbol)
English: The recommended dose is two tablets of Eliquis 5 mg twice a day for the first 7 days, for example, two in the morning and two in the evening.
Croatian: Preporučena doza je dvije tablete lijeka Eliquis 5 mg dvaput na dan tijekom prvih 7 dana, primjerice, dvije ujutro i dvije navečer.
English: Τηλ: +30 210 67 85 800
Croatian: PFIZER ΕΛΛΑΣ Α.Ε. Τηλ: +30 210 67 85 800
English: - Bleeding: - in your brain or in your spinal column, - in your lungs or your throat - in your mouth - into your abdomen or space behind your abdominal cavity - from a haemorrhoid - tests showing blood in the stools or in the urine - Skin rash
Croatian: - Krvarenje: - u mozgu ili kralježnici - u plućima ili grlu - u ustima - u trbuh ili u prostor iza trbušne šupljine - iz hemoroida - pretrage koje pokazuju krv u stolici ili u mokraći - Kožni osip
English: The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group.
Croatian: Utvrđenih velikih krvarenja i klinički značajnih ali ne velikih krvarenja na bilo kojem anatomskom mjestu bilo je općenito manje u skupini liječenoj apiksabanom u odnosu na skupinu liječenu enoksaparinom/varfarinom.
English: The mean age was 69.1 years, the mean CHADS2 score was 2.1 and 18.9% of patients had prior stroke or TIA.
Croatian: Prosječna dob bila je 69,1 godinu, prosječan rezultat na ljestvici CHADS2 2,1, a 18,9% bolesnika prethodno je pretrpjelo moždani udar ili tranzitornu ishemijsku ataku (TIA).
English: Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) 2.5 mg twice daily 67 [30, 153]
Croatian: Liječenje DVT, liječenje PE i prevencija ponavljajućih DVT i PE (VTEt) 2,5 mg dva puta na dan
English: In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA.
Croatian: U ispitivanju AVERROES randomizirano je ukupno 5598 bolesnika koje su ispitivači ocijenili prikladnima za terapiju antagonistom vitamina K, u skupine koje su liječene apiksabanom u dozi od 5 mg dvaput na dan (ili 2,5 mg dvaput na dan u odabranih bolesnika [6,4%], vidjeti dio 4.2) ili ASK-om.
English: - Unit dose blisters in cartons of 60 x 1 and 100 x 1 film-coated tablets for delivery in hospitals are also available.
Croatian: - Dostupni su blisteri s jediničnim dozama sa 60 x 1 i 100 x 1 filmom obloženom tabletom za primjenu u bolnicama.
English: Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40).
Croatian: Apiksaban je u usporedbi s varfarinom smanjio broj slučajeva moždanog udara i sistemske embolije pri različitim razinama centralnog TTR-a; u najvišem kvartilu TTR-a u odnosu na centar omjer hazarda za apiksaban u odnosu na varfarin iznosio je 0,73 (95% CI, 0,38; 1,40).
English: Also, the coadministration of Eliquis with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk.
Croatian: Također, u starijih bolesnika se istodobna primjena lijeka Eliquis i ASK-a mora provoditi oprezno zbog potencijalno povećanog rizika od krvarenja.
English: 10 mg twice daily for the first 7 days 20 mg followed by 5 mg twice daily
Croatian: 20 mg nakon čega slijedi 5 mg dvaput na dan
English: VTE or CV-related death
Croatian: Ponavljajući VTE ili smrtni ishod povezan s CV
English: Anhydrous lactose Microcrystalline cellulose (E460) Croscarmellose sodium Sodium laurilsulfate Magnesium stearate (E470b)
Croatian: Jezgra tablete: laktoza, bezvodna celuloza, mikrokristalična (E460) karmelozanatrij, umrežena natrijev laurilsulfat magnezijev stearat (E470b)
English: In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year.
Croatian: U ispitivanju apiksabana u odnosu na varfarin incidencija velikog gastrointestinalnog krvarenja prema ISTH (uključujući krvarenje u gornjem i donjem dijelu GI trakta i rektalno krvarenje) pri primjeni apiksabana iznosila je 0,76% na godinu.
English: - to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor.
Croatian: - sprječavanje nastanka krvnog ugruška u srcu u bolesnika s nepravilnim otkucajima srca (fibrilacija atrija) u kojih postoji još barem jedan dodatan čimbenik rizika.
English: Adjudicated ISTH major gastrointestinal bleeding occurred in 6 (0.2%) apixaban-treated patients and 17 (0.6%) enoxaparin/warfarin-treated patients.
Croatian: Utvrđeno značajno krvarenje prema Međunarodnom društvu za trombozu i hemostazu (ISTH) pojavilo se u 6 (0,2%) bolesnika liječenih apiksabanom i 17 (0,6%) bolesnika liječenih enoksaparinom/varfarinom.
English: Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets.
Croatian: Nakon peroralne primjene 10 mg apiksabana u obliku 2 zdrobljene tablete od 5 mg suspendirane u 30 ml vode, izloženost je bila usporediva s izloženosti nakon peroralne primjene 2 cijele tablete od 5 mg.
English: Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity.
Croatian: Apiksaban inhibira slobodan faktor Xa, faktor Xa koji je vezan za ugruške te aktivnost protrombinaze.
English: For the prevention of VTE in elective hip or knee replacement surgery (VTEp), the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and
Croatian: Za prevenciju VTE kod elektivnog kirurškog zahvata ugradnje endoproteze kuka ili koljena (VTEp), liječenje DVT, liječenje PE i prevenciju ponavljajućih DVT i PE (VTEt), apiksaban treba primjenjivati uz oprez u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina 15-29 ml/min) (vidjeti dijelove 4.2 i 5.2).
English: How to store Eliquis
Croatian: Kako čuvati Eliquis
English: Temporary discontinuation
Croatian: Privremeni prekid liječenja
English: Bristol-Myers Squibb S.r.l Loc. Fontana del Ceraso 03012 Anagni (FR) Italy
Croatian: Fontana del Ceraso 03012 Anagni (FR) Italija
English: The following side effects are known if you take Eliquis to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.
Croatian: Sljedeće nuspojave mogu nastupiti ako Eliquis uzimate za sprječavanje nastanka krvnog ugruška u srcu u bolesnika s nepravilnim otkucajima srca u kojih postoji još barem jedan dodatan čimbenik rizika.
English: Hepatobiliary disorders Liver function test abnormal, asparate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased
Croatian: Poremećaji jetre i žuči Odstupanja od normalnih vrijednosti testova jetrene funkcije, povišenje aspartat aminotransferaze, povišenje alkalne fosfataze u krvi, povišenje bilirubina u krvi manje često manje često
English: Coadministration of Eliquis and VKA therapy should be continued until the INR is ≥ 2.
Croatian: K treba nastaviti dok INR ne bude ≥ 2.
English: The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John's Wort) may also lead to reduced apixaban plasma concentrations.
Croatian: Istodobna primjena apiksabana s drugim snažnim induktorima CYP3A4 i P-gp-a (npr. fenitoinom, karbamazepinom, fenobarbitalom ili gospinom travom) također može dovesti do smanjenja koncentracije apiksabana u plazmi.
English: - for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;
Croatian: - u liječenju DVT, u liječenju PE i u prevenciji ponavljajućih DVT i PE (VTEt) apiksaban treba primjenjivati uz oprez;
English: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Croatian: Prevencija moždanog udara i sistemske embolije u odraslih bolesnika s nevalvularnom fibrilacijom atrija (NVAF) koji imaju jedan ili više čimbenika rizika poput pretrpljenog moždanog udara ili tranzitorne ishemijske atake (TIA), dobi ≥ 75 godina, hipertenzije, šećerne bolesti, simptomatskog zatajivanja srca (NYHA kategorija ≥ II).
English: Increasing age may increase haemorrhagic risk (see section 5.2).
Croatian: Rizik od krvarenja može se povećati s porastom životne dobi (vidjeti dio 5.2).
English: Apixaban 2.5 mg po twice daily 35 ± 3 d
Croatian: Apiksaban 2,5 mg p.o. dva puta na dan 35 ± 3 d
English: - for the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.
Croatian: - u prevenciji moždanog udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija (NVAF), bolesnici trebaju primati manju dozu apiksabana od 2,5 mg dvaput na dan.
English: After 7 days the recommended dose is one tablet of Eliquis 5 mg twice a day, for example, one in the morning and one in the evening.
Croatian: Nakon 7 dana, preporučena doza je jedna tableta lijeka Eliquis 5 mg dvaput na dan, primjerice, jedna ujutro i jedna navečer.
English: No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE.
Croatian: Kod istodobne primjene s takvim lijekovima nije potrebno prilagođavati dozu apiksabana, ali u bolesnika koji istodobno primaju sistemsku terapiju snažnim induktorima CYP3A4 i P-gp apiksaban treba primjenjivati uz oprez u prevenciji VTE kod elektivnog kirurškog zahvata ugradnje endoproteze kuka ili koljena, u prevenciji moždanog udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija i u prevenciji ponavljajućih DVT i PE.